Disease · MONDO_0007950
mastocytosis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. mastocytosis. Diseases, record MONDO_0007950. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007950
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 2 of its 10 drugs, from DailyMed and EMA Human Drugs
- Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MIDOSTAURIN | CHEMBL608533 | Small molecule | Approval | DailyMed and EMA Human Drugs | 2 | 0 | 0 | Drugs and targets |
| CROMOLYN SODIUM | CHEMBL74 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| HYDROXYCHLOROQUINE | CHEMBL1535 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OMALIZUMAB | CHEMBL1201589 | Antibody | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RUPATADINE | CHEMBL91397 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MASITINIB | CHEMBL1908391 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 2 | 2 | Drugs and targets |
| CROMOLYN | CHEMBL428880 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DASATINIB | CHEMBL5416410 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BORTEZOMIB | CHEMBL325041 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IMATINIB MESYLATE | CHEMBL1642 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets62
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KIT | Mast/stem cell growth factor receptor Kit | 3 | Stem cell growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 3 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/5159 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 2 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 2 | Bcr/Abl fusion protein inhibitor | Phase 2 | https://conductscience.org/library/genes/613 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 2 | Platelet-derived growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/5156 | Drugs and targets |
| ADRM1 | 26S proteasome | 1 | 26S proteasome inhibitor | Early phase 1 | https://conductscience.org/library/genes/11047 | Drugs and targets |
| FGFR3 | Fibroblast growth factor receptor 3 | 1 | Fibroblast growth factor receptor 3 inhibitor | Phase 2 | https://conductscience.org/library/genes/2261 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 1 | Tyrosine-protein kinase receptor FLT3 inhibitor | Approval | https://conductscience.org/library/genes/2322 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 1 | Histamine H1 receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/3269 | Drugs and targets |
| IGHE | Immunoglobulin heavy constant epsilon | 1 | Ig epsilon chain C region inhibitor | Phase 2/3 | https://conductscience.org/library/genes/3497 | Drugs and targets |
1 to 10 of 62
See all 62 targetsTrials9
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00038675 | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | Not applicable | 125 | 2022-01-04 | Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera, Hypereosinophilic Syndrome, Mastocytosis | IMATINIB MESYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT00255346 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | Phase 2 | 68 | 2019-05-06 | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis, Hypereosinophilic Syndrome, Polycythemia Vera, Mastocytosis, Leukemia, Myelomonocytic, Chronic | DASATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT05449444 | Masitinib for the Treatment of Severe Mast Cell Activation Syndrome | Phase 2 | 72 | Mast Cell Activation Syndrome | MASITINIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00437086 | Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders | Early phase 1 | 30 | Chronic Myeloproliferative Disorders, Leukemia | BORTEZOMIB | Its record names the disease | ClinicalTrials.gov | |
| NCT01481909 | Study on Mastocytosis for Rupatadine Treatment | Phase 2/3 | 30 | Mastocytosis | RUPATADINE | Its record names the disease | ClinicalTrials.gov | |
| NCT05084872 | Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients | Phase 2/3 | 30 | Mastocytosis | HYDROXYCHLOROQUINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01266369 | Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation | Phase 2 | 21 | Mastocytosis | MASITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT01333293 | The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients | Phase 2/3 | 17 | Mastocytosis | OMALIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01701843 | Cromoglicate in Mastocytosis | Phase 2 | 7 | Mastocytosis | CROMOLYN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 36048877 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007950
GET https://conductscience.org/api/diseases/v1/MONDO_0007950/targets?page=2